The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
Dec. 15, 2009
|
2 min read
Feb. 20, 2009
|
2 min read